ReviewFrontiers in oncology2018
New Therapies and Immunological Findings in Cutaneous T-Cell Lymphoma.
Review in Frontiers in oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 74 citations in OpenAlex.
- The Significance of the Microenvironment in T/Nk-Cell Neoplasms.International journal of molecular sciences · 2025Review
- Review
- The Progression of Mycosis Fungoides During Treatment with Mogamulizumab: A BIO-MUSE Case Study of the Tumor and Immune Response in Peripheral Blood and Tissue.Biomedicines · 2025Article
- Subcutaneous Panniculitis-Like T-Cell Lymphoma in Children: Two Case Reports.Clinical, cosmetic and investigational dermatology · 2025Article
- Tumors in the setting of dupilumab use: A review of the literature.The World Allergy Organization journal · 2025Review
- CD4/CD8 double-negative mycosis fungoides: a review.Dermatology reports · 2024Review
- Role of IL-4 and IL-13 in Cutaneous T Cell Lymphoma.Life (Basel, Switzerland) · 2024Review
- Subcutaneous Panniculitis-like T-cell Lymphoma Lacking Subcutaneous Tumor Mimicking Adult-onset Still's Disease.Internal medicine (Tokyo, Japan) · 2023Article
- The mycosis fungoides cutaneous microenvironment shapes dysfunctional cell trafficking, antitumor immunity, matrix interactions, and angiogenesis.JCI insight · 2023Article
- Review
- Article
- Subcutaneous panniculitis-like T-cell lymphoma post-mRNA-1273 COVID-19 vaccination.Clinical case reports · 2023Article
- Post-Inflammatory Hypopigmentation: Review of the Etiology, Clinical Manifestations, and Treatment Options.Journal of clinical medicine · 2023Review
- Mycosis fungoides with Psoriasiform plaques: A case report and review of the literature.Clinical case reports · 2023Article
- Review
- Article
- Dermal fibroblasts promote cancer cell proliferation and exhibit fibronectin overexpression in early mycosis fungoides.Journal of dermatological science · 2022Article
- The Role of Tumor Microenvironment in the Pathogenesis of Sézary Syndrome.International journal of molecular sciences · 2022Review
- Expression of Thymic Stromal Lymphopoietin in Immune-Related Dermatoses.Mediators of inflammation · 2022Article
- The Role of Tumor Microenvironment in Mycosis Fungoides and Sézary Syndrome.Annals of dermatology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary cutaneous lymphomas comprise a group of lymphatic malignancies that occur primarily in the skin. They represent the second most common form of extranodal non-Hodgkin's lymphoma and are characterized by heterogeneous clinical, histological, immunological, and molecular features. The most common type is mycosis fungoides and its leukemic variant, Sézary syndrome. Both diseases are considered T-helper cell type 2 (Th2) diseases. Not only the tumor cells but also the tumor microenvironment can promote Th2 differentiation, which is beneficial for the tumor cells because a Th1 environment enhances antitumor immune responses. This Th2-dominant milieu also underlies the infectious susceptibility of the patients. Many components, such as tumor-associated macrophages, cancer-associated fibroblasts, and dendritic cells, as well as humoral factors, such as chemokines and cytokines, establish the tumor microenvironment and can modify tumor cell migration and proliferation. Multiagent chemotherapy often induces immunosuppression, resulting in an increased risk of serious infection and poor tolerance. Therefore, overtreatment should be avoided for these types of lymphomas. Interferons have been shown to increase the time to next treatment to a greater degree than has chemotherapy. The pathogenesis and prognosis of cutaneous T-cell lymphoma (CTCL) differ markedly among the subtypes. In some aggressive subtypes of CTCLs, such as primary cutaneous gamma/delta T-cell lymphoma and primary cutaneous CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.